Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2002-05-23
2004-05-04
Page, Thurman K. (Department: 1615)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S465000, C424S468000, C424S474000, C424S476000, C424S451000, C424S452000, C424S489000, C424S502000, C424S501000, C424S499000, C424S456000, C514S897000
Reexamination Certificate
active
06730319
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field
The present invention relates to pharmaceutical compositions. More particularly, the invention relates to a solid pharmaceutical composition comprising a) a solid pharmaceutically active compound which has a melting point ≧37° C. and b) a fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt, characterized in that the constituents of a) and b) show a depression of their melting points to ≦37° C. upon contact with an aqueous solution.
2. Description
Many pharmaceutically active compounds exhibit low solubilities and low dissolution rates in the biological environment. Examples include cyclosporine, nifedipine, ritonavir, griseofulvin, ubidecarenone, danazol, halofantrine, and tetrahydrolipstatin. Because of the low solubility and the low dissolution rate of the pharmaceutically active compounds, only a certain percentage of the drug molecules is dissolved from the crystals. Undissolved drug crystals exhibit no or very limited therapeutic activity in most cases, independent whether a systemic action (requires drug absorption) or a localized effect (within the lumen of the gastrointestinal tract) is desired. Due to the low dissolution of the active compound, higher doses have to be administrated which might result in an increased danger of side effects. Furthermore it has been found that the presence of food might effect the dissolution, absorption and activity of the compound to a large extend. As an example, the bioavailability of alpha-tocopherol-nicotinate increased 28-fold in the fed status compared to the fasted state [William N. Charman et al.,
J. Pharm. Sci
: 86, 269-282 (1997)]. Other examples include danazol, halofantrine and etretinate. It is obvious for those skilled in the art that the high impact of food on the dissolution of the drug leads to an unpredictable performance of the drug. However, a low variation of the drug dissolution is a necessity to achieve the desired concentration for the pharmaceutically effect and to avoid the toxic effects due to overdosing. A pharmaceutically active compound can only be accepted if a reliable pharmacokinetic profile can be achieved.
The need of the development of drug delivery systems to overcome the high variation of drug dissolution has been widely recognized. Approaches include the development of solid dispersions (“solid solution”) [A. T. M. Serajuddin,
J. Pharm. Sci
., 88, 1058-1066 (1999)]. The main disadvantage of this approach is the thermodynamic instability of the supersaturated solid dispersion, which might lead to crystallization processes leading to decreased dissolution velocities and unpredictable bioavailbilities.
Another approach to decrease the impact of food effects is the production of drug nanoparticules by wet-milling (U.S. Pat. Nos. 4,540,602 and 5,145,684) or High Pressure Homogenization (U.S. Pat. No. 5,858,410). However, disadvantages include the contamination of the product with abrasive material from the milling process. Furthermore, both processes require the presence of suspending liquids and the primary product is a nanosuspension and not dry nanoparticles. The prevention of the increase in particle size due to aggregation or Ostwald ripening is very challenging. Stabilization of the submicrometer sized particles often requires the time and cost intensive removal of the previously added suspension liquid by drying or cryodrying processes. Other disadvantages include the long processing time in wet milling (hours to several days) and the increase in temperature and the possible formation of radicals during the high pressure homogenization process [R. Lander et al.,
Biotechinol. Prog
., 16, 80-15(2000)]. Changes of drug modifications have also to be considered as a result of the milling processes.
It must also be kept in mind, that amorphous drug molecules and drug nanoparticles might degrade faster than the unprocessed material due to the increased surface area. Other approaches include the administration of the solubilized pharmaceutically active compound. However, this approach might lead to problems related to the chemical stability of the active compound, because degradation processes will occur more rapidly in the solubilized state compared to the crystalline state.
For example, lipase inhibitor molecules orlistat (tetrahydrolipstatin), or structurally related compounds, e.g. 2-oxy-4H-3,1-benzoxanzin-4-ones as described in WO00/40569, or 2-oxo amide triacylglycerol analogues [S. Kotsovolou et al.,
J. Org. Chem
., 66: 962-967 (2001)] are molecules that may degrade during storage by different mechanisms. It is well known that degradation velocity depends to a large extent from the physicochemical state of the active compound. In general, drug crystals have higher chemical stability compared to drug molecules in the amorphous or liquid state. Therefore, for good storage stability it is desirable to incorporate drug molecules in the crystalline form into the drug delivery system. It is, however, also well known, that in most cases pharmacoactivity is related to physicochemical states with high mobility, e.g. the solubilized or molten molecule. Therefore, from the point of pharmacoactivity, the drug molecule must be either given in a solubilized form or transform into a solubilized form within the body.
Both stability and activity aspects have to be considered. Therefore, the development of a drug-crystal loaded carrier which releases a solubilized drug is the most desirable case. This concept is easily realized for water-soluble drugs (e.g. ascorbic acid). However, the in situ transformation of poor water-soluble drugs remains a challenge.
The subject invention addresses this challenge.
SUMMARY OF THE INVENTION
The subject invention provides a solid pharmaceutical composition, which comprises a solid pharmaceutically active compound that has a melting point ≧37° C., and a fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt. The pharmaceutically active compound and the fatty acid or a fatty acid salt or a mixture of a fatty acid and a fatty acid salt are present in amounts such that when the composition is contacted with an aqueous solution having a pH value ≦8, the melting point of the composition is less than the melting point of the solid pharmaceutically active compound and ≦37° C.
REFERENCES:
patent: 4540602 (1985-09-01), Motoyama et al.
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 5145684 (1992-09-01), Liversidge et al.
patent: 5858410 (1999-01-01), Muller et al.
patent: 32 17071 (1983-11-01), None
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 0465 423 (1992-01-01), None
patent: 524 495 (1993-01-01), None
patent: 901 792 (1999-03-01), None
patent: WO 99/33450 (1999-07-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/09122 (2000-02-01), None
patent: WO 00/40569 (2000-07-01), None
patent: WO 01/19340 (2001-03-01), None
patent: WO 01/19340 (2001-03-01), None
patent: WO 01/19378 (2001-03-01), None
patent: WO 01/32616 (2001-05-01), None
patent: WO 01/32669 (2001-05-01), None
patent: WO 01/32670 (2001-05-01), None
Kotsovolou et al., J. Org. Chem., 66, pp. 962-967 (2001).
Mutoh et al., J. of Antibiot., 47, pp. 1369-1375 (1994).
Charman et al., J. Pharm. Sci., 86, pp. 269-282 (1997).
Serajuddin, A., J. Pharm. Sci., 88, pp. 1058-1066 (1999).
Lander et al., Biotechnol. Prog., 16, pp. 80-85 (2000).
Maeder Karsten
Scheibler Lukas Christoph
Steffen Hans
Bennett Rachel M.
Hoffmann-La Roche Inc.
Johnston George W.
Page Thurman K.
Parise John P.
LandOfFree
Pharmaceutical compositions having depressed melting points does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions having depressed melting points, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions having depressed melting points will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3243753